A phase II, controlled, randomized, multicentre, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine with various doses of the AS03 adjuvant compared to Fluarix (GlaxoSmithKline Biologicals) administered intramuscularly in subjects aged 18-64 years
Latest Information Update: 17 Sep 2021
At a glance
- Drugs GSK 1247446A (Primary) ; AS03A; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Acronyms FLU-LD-012
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
- 04 May 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 28 Jun 2012 Official title amended as reported by European Clinical Trials Database.
- 23 Oct 2008 Primary outcome added as reported by ClinicalTrials.gov.